Pfizer has been forced to discontinue its oral GLP-1 receptor agonist danuglipron after seeing signs of liver toxicity in late-stage clinical testing. The decision is a massive blow to Pfizer's ...

Pfizer has revealed that its much-anticipated selective oestrogen receptor degrader (SERD) vepdegestrant for breast cancer missed the mark for a key endpoint in its first phase 3 trial readout.

Story May 1 - Arvinas: After Arvinas announced during its Q1 results presentation that the biotech and partner Pfizer are dropping two phase 3 trials from their estrogen receptor degrader R&D plan ...

The world’s largest group of oil producers, OPEC+, stuck to its guns on Saturday with another big increase of 411,000 barrels per day for July as it looks to wrestle back market share and punish ...